Cell No. : Cell Name
RCB5683 : ASPS-KY
update : 2024/11/11
|
| Comment | |
| Comment from the depositor | Human cell line derived from alveolar soft part sarcoma. |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Expected time |
Upon a request we will start preparation. Contact us: cellkitaku.brc@riken.jp
|
| Depositor |
MIYAGI, Youhei
|
| Originator |
KUSHIDA, Kazuyoshi & YANOMA, Shunsuke
|
| Animal |
_human
< Mammals
|
| Strain name |
Homo
|
| Genus |
sapiens
|
| Gender |
Female
|
| Age at sampling |
27 years
|
| Tissue |
lung meta
|
| Primary focus |
lower leg
|
| Disease name |
alveolar soft part sarcoma
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
lumg
|
| Classification |
cancer
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Product |
HGF, IL-8
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Adherent cells
|
Adherent cells
|
| Culture medium |
RPMI1640 + 10% FCS
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1: 3-4 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
Medium + 10% DMSO
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| Virus |
|
OK
|
| Reference information |
Reference |
11
|
| User's Publication |
0
|
| Reference |
|
16681
Mukaihara K, Tanabe Y, Kubota D, Akaike K, Hayashi T, Mogushi K, Hosoya M, Sato S, Kobayashi E, Okubo T, Kim Y, Kohsaka S, Saito T, Kaneko K, Suehara Y.
Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma
PLoS One
2017
12(9):e0185321
PubMed ID: 28945796
DOI: 10.1371/journal.pone.0185321
|
|
16674
Kim Y, Kobayashi E, Kubota D, Suehara Y, Mukaihara K, Akaike K, Ito A, Kaneko K, Chuman H, Kawai A, Kitano S.
Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance
Oncotarget
2016
7(43):70832-70844
PubMed ID: 27683125
DOI: 10.18632/oncotarget.12225
|
|
16682
Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, Demetri GD, Wagner AJ.
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
Oncotarget
2016
7(13):16581-92
PubMed ID: 26918731
DOI: 10.18632/oncotarget.7667
|
|
16680
Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N.
Effect of temozolomide on the viability of musculoskeletal sarcoma cells
Oncol Lett
2015
10(4):2511-2518
PubMed ID: 26622881
DOI: 10.3892/ol.2015.3506
|
|
16684
Kubota D, Yoshida A, Kawai A, Kondo T.
Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma
J Proteome Res
2014
13(5):2250-61
PubMed ID: 24621013
DOI: 10.1021/pr400929h
|
|
16683
Li GD, Kawashima H, Ogose A, Ariizumi T, Hotta T, Kuwano R, Urata Y, Fujiwara T, Endo N.
Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells
Cancer Sci
2013
104(9):1178-88
PubMed ID: 23718223
DOI: 10.1111/cas.12208
|
|
16676
Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezu H, Endo N.
High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis
Oncol Rep
2011
25(3):599-60
PubMed ID: 21234520
DOI: 10.3892/or.2011.1141
|
|
16679
Li G, Kawashima H, Ji L, Ogose A, Ariizumi T, Umezu H, Xu Y, Hotta T, Endo N.
Frequent absence of tumor suppressor FUS1 protein expression in human bone and soft tissue sarcomas
Anticancer Res
2011
31(1):11-21
PubMed ID: 21273575
|
|
16685
Hoshino M, Ogose A, Kawashima H, Izumi T, Hotta T, Hatano H, Morita T, Otsuka H, Umezu H, Yanoma S, Tsukuda M, Endo N.
Molecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcoma
Cancer Genet Cytogenet
2009
190(2):75-80
PubMed ID: 19380023
DOI: 10.1016/j.cancergencyto.2008.11.014
|
|
16677
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A.
UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme
Cancer Res
2003
63(14):4167-73
PubMed ID: 12874022
|
|
16675
Hanaoka E, Ozaki T, Nakamura Y, Moriya H, Nakagawara A, Sakiyama S.
Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells
Biochem Biophys Res Commun
2000
278(1):20-6
PubMed ID: 11071849
DOI: 10.1006/bbrc.2000.3758
|
Back
Top
CELL BANK Website